Peptides DB
Research-centric peptide and protocol reference hub
Study 9 of 45HCG (Human Chorionic Gonadotropin) literatureeuropepmc · Observational2026

ICSI shows no advantage over conventional IVF in patients with unexpected low oocyte yield.

In patients with fewer than five oocytes, ICSI does not show a significant advantage over conventional IVF based on embryo and pregnancy outcomes.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the hcg (human chorionic gonadotropin) corpus
9
Preclinical
31
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This study compared the outcomes of conventional IVF (C-IVF) and ICSI in patients with unexpectedly low oocyte yield, specifically those with 3 or 4 oocytes retrieved. A total of 424 C-IVF cycles and 90 ICSI cycles were analyzed. The results indicated no significant advantage for ICSI over C-IVF in terms of embryo and pregnancy outcomes.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Day 3 good quality embryo rate: 59.76% IVF-LN vs 47.46% ICSI-LN; p < 0.01.2026

Abstract

The authors’ words, as europepmc supplied them

<h4>Background</h4>A yield of fewer than five oocytes is associated with a sharp drop in success rates, making each oocyte extremely valuable and demanding highly efficient utilization. Therefore, we aimed to explore the optimal fertilization method for these patients.<h4>Methods</h4>This retrospective cohort single-center study included 424 C-IVF cycles and 90 ICSI cycles from 2016 to 2023. All patients were in their first ART cycle, with 3 or 4 oocytes retrieved. The study subjects were primarily divided into two groups: the IVF-LN (C-IVF with a 50% lower-than-expected oocyte yield) group and the ICSI-LN (ICSI with a 50% lower-than-expected oocyte yield) group.<h4>Results</h4>We observed no significant differences in the day 3 available embryo (87.0 versus 84.8%; <i>p</i> = 0.41), blastocyst formation (61.2 versus 57.9%; <i>p</i> = 0.69), day 5 blastocyst (56.9 versus 54.5%; <i>p</i> = 0.83) or good quality blastocyst (45.4 versus 50.0%; <i>p</i> = 0.83) rates between the IVF-LN and ICSI-LN groups. However, the day 3 good quality embryo rate was significantly higher in the IVF-LN group than in the ICSI-LN group (59.76% vs. 47.46%; <i>p</i> < 0.01). There were no significant differences in the pregnancy (61.8 versus 57.7%; <i>p</i> = 0.50), clinical pregnancy (59.1 versus 53.8%; <i>p</i> = 0.40), ongoing pregnancy (52.2 versus 47.4%; <i>p</i> = 0.45) or live birth (48.6 versus 44.9%; <i>p</i> = 0.55) rates between the IVF-LN and ICSI-LN groups.<h4>Conclusion</h4>For patients with <5 Oocytes and a predicted yield of ≤50%, ICSI did not demonstrate a significant advantage over C-IVF.

Background

The study addresses the clinical question of whether ICSI provides a benefit over conventional IVF in patients who yield unexpectedly low numbers of oocytes. Prior research has shown mixed results regarding the efficacy of ICSI in various populations, making this investigation relevant for optimizing fertility treatments. Understanding the comparative effectiveness in low oocyte yield cases could influence clinical decision-making.

Methods

The study design, population characteristics, sample size, dosage, duration, and specific outcome measures were not reported in the abstract. Therefore, details regarding the methodology remain unclear.

Results

The primary endpoint and specific results were not reported in the abstract, limiting the ability to summarize findings accurately.

Interpretation

Due to the lack of reported results, it is not possible to compare the findings to existing literature or assess the clinical significance of any observed effects. Without numeric data, the implications for practice remain uncertain.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the HCG (Human Chorionic Gonadotropin) corpus

BAnalytical performance comparison of Siemens Atellica CI1900 and Roche Cobas Pure integrated analyzers across spectrophotometric, ion-selective electrode and immunoassay parameters.Analytical biochemistry · 2026 · n=464 · R2 ≥ 0.95 for ALT, total bilirubin, glucose, and creatinine in spectrophotometric assays.reviewChCG promotes secondary ovulation and supplementary corpus luteum formation during early pregnancy in mares.Theriogenology · 2026 · n=30 · 82.4% of hCG-treated mares ovulated within 48 h vs 0% in control, P<0.0001.AnimalBImpact of early postoperative human chorionic gonadotropin change direction after high-intensity focused ultrasound on ultrasound-guided dilation and curettage outcomes in cesarean scar pregnancy: a retrospective study.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · n=210 · β-hCG on post-curettage day 1 remained higher in the rising group, p<0.05.HumanDTrastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.The New England journal of medicine · 2026BEfficacy of Gonadotropin Therapy to Induce Spermatogenesis and Fertility in Men with Pathologic Gonadotropin Deficiency.The Journal of clinical endocrinology and metabolism · 2026 · 78% achieved >0 million sperm/mL at 5 months.HumanBImpact of early postoperative human chorionic gonadotropin change direction after high-intensity focused ultrasound on ultrasound-guided dilation and curettage outcomes in cesarean scar pregnancy: a retrospective study.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · β-hCG on post-curettage day 1 remained higher in the rising group, p<0.05.Human